AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial involvement
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraoropharyngeal involvement
Number of subjects: 677
Study 10570413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral spread to the medial infratemporal fossa
Number of subjects: 677
Study 8649495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy and autologous bone marrow transplantation
Number of subjects: 200
Study 8649495 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 200
Study 1951216 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcomputer-based tutorial (Group C)
Number of subjects: 0
Study 1951216 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific reading material (Group B)
Number of subjects: 0
Study 1951216 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 0
Study 6299503 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pelvic x-ray therapy plus a perineal proton beam boost (500 to 700 cGy dose to prostatic tumor)
Number of subjects: 180
Study 6299503 — intervention group
Group type: COMPARATOR
Intervention: Conventional pelvic megavoltage x-ray therapy
Number of subjects: 180
Study 31154818 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 31154818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28678849 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMPION intervention package (community health promotion and provision of health services)
Number of subjects: 29669
Study 28678849 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMPION intervention package
Number of subjects: 29669
Study 26860023 — intervention group
Group type: EXPERIMENTAL
Intervention: 20.25 mg of hyperbaric ropivacaine in 5% dextrose (group B)
Number of subjects: 80
Study 26860023 — intervention group
Group type: COMPARATOR
Intervention: 20.25 mg of plain ropivacaine (group A)
Number of subjects: 80
Study 22840340 — intervention group
Group type: EXPERIMENTAL
Intervention: VCS clips
Number of subjects: 24
Study 22840340 — intervention group
Group type: COMPARATOR
Intervention: Prolene sutures
Number of subjects: 24
Study 21163558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil
Number of subjects: 60
Study 21163558 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg/day)
Number of subjects: 60
Study 21163558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (sesame oil + glibenclamide)
Number of subjects: 60
Study 21163558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 60
Study 19570039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 0
Study 19570039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 0
Study 19570039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 0
Study 19570039 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 0
Study 17115133 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (FIO2 50%, PEEP 5 cmH2O) with 4Vent helmet
Number of subjects: 5
Study 17115133 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (FIO2 50%, PEEP 5 cmH2O) with PN500 helmet
Number of subjects: 5
Study 17115133 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (FIO2 50%, PEEP 5 cmH2O) with CaStar helmet
Number of subjects: 5
Study 17115133 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with safety valve open
Number of subjects: 5
Study 17115133 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with safety valve locked
Number of subjects: 5
Study 15036782 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual exposure among freshman college roommates over seven months
Number of subjects: 0
Study 15036782 — intervention group
Group type: COMPARATOR
Intervention: Best friends in third grade classrooms
Number of subjects: 0
Study 12170362 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methyl prednisolone (30 mg/kg)
Number of subjects: 30
Study 12170362 — intervention group
Group type: COMPARATOR
Intervention: Low-dose methyl prednisolone (2 mg/kg)
Number of subjects: 30
Study 10660865 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine supplementation (10,000 mg.d‐1)
Number of subjects: 7
Study 7749832 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment with INR < 1.7
Number of subjects: 74
Study 7749832 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment with INR 1.7 to 2.5
Number of subjects: 74
Study 7749832 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment with INR > 2.5
Number of subjects: 74
Study 7749832 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment (general)
Number of subjects: 74
Study 7749832 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment in patients with congenital antithrombin III or protein C deficiency
Number of subjects: 74
Study 7749832 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin discontinuation in one patient
Number of subjects: 74
Study 2301259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic treadmill exercise
Number of subjects: 11
Study 2301259 — intervention group
Group type: EXPERIMENTAL
Intervention: Isodynamic exercise (treadmill walking 1.5 to 2.0 mph carrying 15 to 25 kg)
Number of subjects: 11
Study 2301259 — intervention group
Group type: COMPARATOR
Intervention: Baseline submaximal treadmill exercise test
Number of subjects: 11
Study 7461761 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-G
Number of subjects: 0
Study 7461761 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-B
Number of subjects: 0
Study 7461761 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-A
Number of subjects: 0
Study 7461761 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-F
Number of subjects: 0
Study 6136059 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot neuroleptics (fluphenazine decanoate or flupenthixol decanoate)
Number of subjects: 41
Study 6136059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 6136059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 41
Study 6136059 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 41
Study 29401082 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed initiation of oral feeding (1 week later)
Number of subjects: 40
Study 29401082 — intervention group
Group type: COMPARATOR
Intervention: Control group (started oral feeding when physiologically stable)
Number of subjects: 40
Study 29401082 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 40
Study 26360934 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person group intervention composed of six 90-min sessions over 4 weeks with follow-up phone calls
Number of subjects: 131
Study 26360934 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study 26360934 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person group intervention
Number of subjects: 131
Study 24788974 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally independent group
Number of subjects: 19748
Study 24788974 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally partially dependent group
Number of subjects: 19748
Study 24788974 — intervention group
Group type: COMPARATOR
Intervention: Functionally partially dependent vs. functionally independent
Number of subjects: 19748
Study 22564241 — intervention group
Group type: EXPERIMENTAL
Intervention: WATERCISE group (aqua-training programme once a week for 1 h over 12 months)
Number of subjects: 28
Study 22564241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aqua-training)
Number of subjects: 28
Study 22564241 — intervention group
Group type: EXPERIMENTAL
Intervention: WATERCISE group
Number of subjects: 28
Study 20029984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (group A)
Number of subjects: 562
Study 20029984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (group B)
Number of subjects: 562
Study 18416725 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (temporary restoration on the day of surgery)
Number of subjects: 266
Study 18416725 — intervention group
Group type: COMPARATOR
Intervention: Early loading (temporary restoration 28-34 days after surgery)
Number of subjects: 266
Study 15671185 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care (active treatment with practice nurses for 24 months)
Number of subjects: 211
Study 15671185 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care
Number of subjects: 211
Study 12791219 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics administered before surgical evaluation
Number of subjects: 0
Study 10496260 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) carbidopa/levodopa
Number of subjects: 618
Study 10496260 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) carbidopa/levodopa
Number of subjects: 618
Study 7793557 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 ml applied locally to the knee at the end of the procedure (n = 30)
Number of subjects: 60
Study 7793557 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg intramuscularly (n = 30)
Number of subjects: 60
Study 1771701 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg trospium chloride twice daily for 3 weeks
Number of subjects: 61
Study 1771701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 7044532 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin chemotherapy with radiation therapy
Number of subjects: 107
Study 7044532 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole immunotherapy with radiation therapy
Number of subjects: 107
Study 7044532 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 107
Study 7044532 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arms with chemotherapy and/or immunotherapy
Number of subjects: 107
Study 31918243 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-phonetic treatment
Number of subjects: 8
Study 31918243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phonetic-phonological treatment
Number of subjects: 8
Study 30477763 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous treprostinil (target dose around 30 ng/kg per min at week 12)
Number of subjects: 105
Study 30477763 — intervention group
Group type: COMPARATOR
Intervention: Low-dose subcutaneous treprostinil (target dose around 3 ng/kg per min at week 12)
Number of subjects: 105
Study 30477763 — intervention group
Group type: COMPARATOR
Intervention: Comparison of high-dose vs low-dose subcutaneous treprostinil
Number of subjects: 105
Study 30477763 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous treprostinil
Number of subjects: 105
Study 30477763 — intervention group
Group type: COMPARATOR
Intervention: Low-dose subcutaneous treprostinil
Number of subjects: 105
Study 26919407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavuplasty (creating a small cavity in the vertebral body prior to cement injection)
Number of subjects: 36
Study 26919407 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty (control)
Number of subjects: 36
Study 27385833 — intervention group
Group type: EXPERIMENTAL
Intervention: Two consecutive real cervical spinal manipulative therapy (SMT) interventions to C5‐C6 segment
Number of subjects: 26
Study 27385833 — intervention group
Group type: COMPARATOR
Intervention: One real SMT followed by one validated sham SMT intervention to C5‐C6 segment
Number of subjects: 26
Study 25103358 — intervention group
Group type: EXPERIMENTAL
Intervention: EASY Minds program (curriculum-based physical activity integration program)
Number of subjects: 8
Study 25103358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8
Study 21936966 — intervention group
Group type: COMPARATOR
Intervention: Selenomethionine (SeMet) supplementation at doses of 0, 50, 100, or 200 μg/d
Number of subjects: 261
Study 21936966 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (SeMet) supplementation
Number of subjects: 261
Study 19092145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (target glycated hemoglobin reduction of 1.5 percentage points)
Number of subjects: 1791
Study 19092145 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control (mean glycated hemoglobin level 8.4%)
Number of subjects: 1791
Study 19092145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 1791
Study 19092145 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 1791
Study 17600165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior treatment (CBT)
Number of subjects: 140
Study 17600165 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 140
Study 15679008 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic CPAP (AutoSet T, ResMed, Sydney, Australia)
Number of subjects: 20
Study 15679008 — intervention group
Group type: COMPARATOR
Intervention: Fixed level CPAP
Number of subjects: 20
Study 11464715 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha levels in cerebrospinal fluid and serum in patients with stroke
Number of subjects: 30
Study 11464715 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients with tension headache and neurasthenia)
Number of subjects: 30
Study 9972055 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery embolization
Number of subjects: 45
Study 9972055 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 45
Study 9972055 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with renal cancer before embolization
Number of subjects: 45
Study 8145914 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg Dihydroergotamine (DHE) nasal spray (0.5 mg per nostril, repeated after 15 minutes)
Number of subjects: 112
Study 8145914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 3062540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine solution 0.5% (1 drop 3 times daily)
Number of subjects: 118
Study 3062540 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle solution
Number of subjects: 118
Study 3062540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine solution 0.5%
Number of subjects: 118
Study 31734805 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral‐Approach group
Number of subjects: 71
Study 31734805 — intervention group
Group type: COMPARATOR
Intervention: Bilateral‐Approach group
Number of subjects: 71
Study 31407622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushen capsule
Number of subjects: 70
Study 31407622 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba
Number of subjects: 70
Study 31407622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushen capsule and Ginkgo biloba
Number of subjects: 70
Study 29148175 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cocktail (Lactobacilli, Bifidobacteria, and Streptococcus thermophilus) once daily for 12 weeks
Number of subjects: 75
Study 29148175 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cocktail
Number of subjects: 75
Study 29148175 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-fat/low-calorie diet only)
Number of subjects: 75
Study 25846824 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADL) score <12 of 15
Number of subjects: 734
Study 25846824 — intervention group
Group type: EXPERIMENTAL
Intervention: Braden Scale score <16
Number of subjects: 734
Study 25846824 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL score <12 of 15
Number of subjects: 734
Study 23452547 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized pre-packaged artemether-lumefantrine (AL) with training for retail staff
Number of subjects: 564
Study 21894687 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye acupuncture therapy
Number of subjects: 110
Study 21894687 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen Sustained Release Capsules, 300 mg orally, 1-2 days before menses or when symptoms appeared, every 12 hours for 3-5 days
Number of subjects: 110
Study 19250683 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 108
Study 19250683 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (NaRI)
Number of subjects: 108
Study 16739330 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose neoadjuvant treatment with cyclophosphamide and epirubicin
Number of subjects: 37
Study 15324983 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimenopausal health education intervention (health education brochure, one-on-one teaching)
Number of subjects: 353
Study 15324983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 353
Study 11511713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra) 50 mg
Number of subjects: 24
Study 11511713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9012686 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuG‐CSF (Lenograstim) 2.5 micrograms/kg
Number of subjects: 0
Study 9012686 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuG‐CSF (Lenograstim) 5.0 micrograms/kg
Number of subjects: 0
Study 9012686 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuG‐CSF (Lenograstim) 7.5 micrograms/kg
Number of subjects: 0
Study 8453943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 81
Study 3862426 — intervention group
Group type: EXPERIMENTAL
Intervention: Epostane
Number of subjects: 20
Study 3862426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31692559 — intervention group
Group type: EXPERIMENTAL
Intervention: DemenTalent (part of iMCSP)
Number of subjects: 0
Study 31692559 — intervention group
Group type: EXPERIMENTAL
Intervention: DemenTalent and regular MCSP
Number of subjects: 0
Study 31692559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementelcoach (part of iMCSP)
Number of subjects: 0
Study 31692559 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR e‐Learning (part of iMCSP)
Number of subjects: 0
Study 31692559 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular MCSP
Number of subjects: 0
Study 31692559 — intervention group
Group type: COMPARATOR
Intervention: No day care support
Number of subjects: 0
Study 29269513 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐986120 (60 mg)
Number of subjects: 40
Study 29269513 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (600 mg)
Number of subjects: 40
Study 25939641 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 110
Study 25939641 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking + facilitated tucking
Number of subjects: 110
Study 25939641 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose + facilitated tucking
Number of subjects: 110
Study 25939641 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking + oral sucrose
Number of subjects: 110
Study 25939641 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking + oral sucrose + facilitated tucking
Number of subjects: 110
Study 24211236 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 12
Study 24211236 — intervention group
Group type: COMPARATOR
Intervention: Normal night sleep
Number of subjects: 12
Study 21458326 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM (Intermediate Restorative Material)
Number of subjects: 164
Study 21458326 — intervention group
Group type: COMPARATOR
Intervention: Super-EBA (Super Ethoxybenzoic Acid)
Number of subjects: 164
Study 19406976 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg phosphorus meal
Number of subjects: 11
Study 19406976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg phosphorus meal
Number of subjects: 11
Study 17446813 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12253
Study 15123865 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial exchange transfusion using isotonic saline within 4 hours of screening
Number of subjects: 45
Study 15123865 — intervention group
Group type: COMPARATOR
Intervention: Routine medical management
Number of subjects: 45
Study 11773672 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (specific intervention not detailed)
Number of subjects: 0
Study 11773672 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug development model (implied control)
Number of subjects: 0
Study 8055894 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (75 g)
Number of subjects: 11
Study 8055894 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (75 g)
Number of subjects: 11
Study 8055894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (W)
Number of subjects: 11
Study 3143239 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 40
Study 3143239 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 40
Study 31049205 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical deprescribing trials
Number of subjects: 96
Study 31049205 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to conducting deprescribing trials
Number of subjects: 96
Study 31049205 — intervention group
Group type: EXPERIMENTAL
Intervention: Enablers of conducting deprescribing trials
Number of subjects: 96
Study 31049205 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodology for deprescribing trials
Number of subjects: 96
Study 31049205 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for clinical practice framework
Number of subjects: 96
Study 31049205 — intervention group
Group type: COMPARATOR
Intervention: Previous experience in conducting deprescribing trials
Number of subjects: 96
Study 31049205 — intervention group
Group type: EXPERIMENTAL
Intervention: Future deprescribing trial framework
Number of subjects: 96